Mammalian Target of Rapamycin Pathway Assessment in Antiphospholipid Antibody Positive Patients with Livedo.,The Journal of Rheumatology

当前位置： X-MOL 学术 › J. Rheumatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Mammalian Target of Rapamycin Pathway Assessment in Antiphospholipid Antibody Positive Patients with Livedo.
The Journal of Rheumatology ( IF 3.9 ) Pub Date : 2022-06-01 , DOI: 10.3899/jrheum.220049
Ecem Sevim ₁ , Salma Siddique ₂ , Madhavi Latha S Chalasani ₃ , Susan Chyou ₄ , William D Shipman ₅ , Orla O'Shea ₄ , Joanna Harp ₆ , Oral Alpan ₇ , Stéphane Zuily ₈ , Theresa T Lu ₃ , Doruk Erkan ₉

Affiliation

E. Sevim, MD, Department of Rheumatology, Hospital for Special Surgery, New York, and Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA;
S. Siddique, DO, Pediatric Rheumatology, Hospital for Special Surgery, New York, New York, now with Nemours Alfred I. DuPont Hospital for Children, Wilmington, Delaware, USA.
M.L.S. Chalasani, PhD, T.T. Lu, MD, PhD, Pediatric Rheumatology, Hospital for Special Surgery, Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute, and Department of Microbiology and Immunology, Weill Cornell Medicine, New York, New York, USA.
S. Chyou, BA, O. O'Shea, MS, Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute, New York, New York, USA.
W.D. Shipman, BS, Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute, and Weill Cornell Tri-Institutional MD-PhD Program, New York, New York, USA.
J. Harp, MD, Department of Dermatology, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, New York, USA.
O. Alpan, MD, O&O Alpan, LLC, Fairfax, Virginia, USA.
S. Zuily, MD, MPH, PhD, CHRU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, and Inserm U1116 at Lorraine University, Nancy, France.
D. Erkan, MD, MPH, Department of Rheumatology, Hospital for Special Surgery, and Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery and Weill Cornell Medicine, New York, NY, USA.

In antiphospholipid antibody (aPL) nephropathy, activation of the mammalian target of rapamycin (mTOR) contributes to endothelial cell proliferation, a key finding of aPL microvascular disease. Here, we examined mTOR activation in the skin of aPL-positive patients with livedo.

中文翻译：